ISSN: 2476-2067

Токсикология: открытый доступ

Открытый доступ

Наша группа организует более 3000 глобальных конференций Ежегодные мероприятия в США, Европе и США. Азия при поддержке еще 1000 научных обществ и публикует более 700 Открытого доступа Журналы, в которых представлены более 50 000 выдающихся деятелей, авторитетных учёных, входящих в редколлегии.

 

Журналы открытого доступа набирают больше читателей и цитируемости
700 журналов и 15 000 000 читателей Каждый журнал получает более 25 000 читателей

Абстрактный

Pseudomonal Bacteremia and Cefepime-Induced Neurotoxicity: A Case Report

Megan Smith, Chris Mehdizadeh, Avrodet Mourkus, Saad Ansari A

Cefepime is a broad-spectrum fourth-generation cephalosporin with activity against both gram positive and negative bacteria, including Pseudomonas aeruginosa [1]. Cefepime is most commonly used for urinary tract infections, soft tissue infections, and febrile neutropenia [2]. Up to 15% of ICU patients on cefepime may experience cefepime-induced neurotoxicity, with risk factors including renal dysfunction, excessive dosage, elevated serum cefepime concentrations, and history of prior brain injury [3].

The adverse effects of cefepime-induced neurotoxicity including encephalopathy, seizures, and coma can be resolved with drug cessation, antiepileptics, or hemodialysis [3]. Here, we present the case of cefepime induced neurotoxicity in a 59-year-old female patient with long-term cefepime antibiotic prescription for Pseudomonal endocarditis and bacteremia with multiple risk factors for reduced renal function. We discuss the relevant risk factors and preventive measures that may have prevented her from developing encephalopathy, as well as the importance of early recognition and prevention of cefepime-induced neurotoxicity in patient care.